Can fluconazole concentrations in saliva be used for therapeutic drug monitoring?
The saliva/plasma concentration ratio of fluconazole was investigated in 22 HIV-1-infected individuals with an oropharyngeal Candida infection to determine whether saliva fluconazole concentrations could provide useful information for therapeutic drug monitoring in this population. Steady-state paired plasma and saliva samples were obtained after approximately 1 week of treatment with 50-or 100-mg fluconazole as capsules. A significant correlation between plasma and salivary levels of fluconazole was observed. The median saliva/plasma concentration ratio was 1.3 and was independent of the ingested dose and the plasma fluconazole concentration. The prediction of fluconazole concentrations in plasma from the concentrations in saliva was, although unbiased, not precise. From these findings, the authors conclude that although stimulated salivary fluconazole concentrations are significantly correlated with plasma concentrations, it is not possible to predict plasma fluconazole levels from the salivary concentrations with adequate precision. However, saliva fluconazole concentrations have sufficient value to test for compliance and even semiquantitative prediction of plasma concentrations.
Koks
C H
CH
Department of Pharmacy and Pharmacology, Slotervaart Hospital, Amsterdam, The Netherlands. Apkko@slz.nl
Crommentuyn
K M
KM
Hoetelmans
R M
RM
Mathôt
R A
RA
Beijnen
J H
JH
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy / Q000378:metabolism* / Q000382:microbiology; D000328:Adult; D000368:Aged; D000935:Antifungal Agents / Q000493:pharmacokinetics*; D002180:Candidiasis, Oral / Q000188:drug therapy / Q000378:metabolism* / Q000382:microbiology; D016903:Drug Monitoring; D015725:Fluconazole / Q000493:pharmacokinetics*; D006801:Humans; D008875:Middle Aged; D012463:Saliva / Q000378:metabolism*
D000935:Antifungal Agents; D015725:Fluconazole